Моторикс

Quick links to important sections

Моторикс

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Моторикс

What is Моторикс? - Overview

Property Description
Active ingredient Domperidone (INN)
Form Tablets (film-coated), Oral Suspension
Pharmacological class Dopamine Antagonist, Prokinetic Agent
Common use Relief of symptoms associated with slow gastrointestinal movement
Origin Synthetic benzimidazole derivative

What Type of Medicine is Моторикс (Domperidone)?

Моторикс is a prescription-only (Rx) medicinal product whose active compound is Domperidone (INN). It is a synthetic benzimidazole derivative classified as both a Dopamine Antagonist and a Prokinetic Agent. The medication has a peripheral mechanism of action, making it a distinct choice within its class for targeting the digestive tract. The positioning of this medication often focuses on adult and adolescent patient groups experiencing issues with gastric motility.

Composition and Available Pharmaceutical Forms

The formulation relies exclusively on the single active substance, Domperidone. It is supplied in different oral dosage forms, commonly including film-coated tablets and a liquid oral suspension. The existence of multiple preparations ensures flexible administration, facilitating the consistent introduction of the single active compound into the body.

General Purpose: What Does It Help To Do?

The general purpose of Моторикс is to help normalize the coordinated movement (motility) of the upper digestive tract. By blocking specific peripheral dopamine receptors, it helps stimulate organized muscle contractions and increases the muscle tone of the lower esophageal valve. This mechanism facilitates efficient gastric emptying and subsequently helps to alleviate discomfort associated with sluggish digestion, including feelings of nausea and the urge to vomit. A typical neutral use scenario involves managing postprandial fullness related to delayed stomach clearance.

What side effects are possible with Моторикс?

Possible Side Effects and Safety Information

The safety profile of Domperidone (Моторикс) is defined by officially documented adverse reactions categorized by their frequency, which primarily include effects on the central nervous system, gastrointestinal tract, and cardiovascular system. The most common adverse reaction documented in regulatory sources is dry mouth.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency as follows, based on official regulatory standards:

  • Common (may affect up to 1 in 10 people): Dry mouth.
  • Uncommon (may affect up to 1 in 100 people): Headache, somnolence, anxiety, agitation, diarrhea, rash, pruritus, asthenia, and certain effects related to the reproductive system (e.g., breast pain, galactorrhea).
  • Very Rare or Frequency Not Known: This group includes serious events such as Torsades de Pointes, ventricular arrhythmia, and sudden cardiac death. Rare hypersensitivity reactions like anaphylactic shock and neurological issues like convulsion and extrapyramidal disorder are also documented.

Safety Constraints and Special Populations

Official labeling contains specific constraints on use. The medicine is contraindicated in patients with pre-existing heart conditions, significant electrolyte disturbances, or severe-to-moderate hepatic impairment. Use is also restricted in situations where gastrointestinal stimulation would be harmful, such as in the presence of hemorrhage or perforation.

Regulatory documents emphasize that the risk of serious cardiac adverse reactions is a key constraint, leading to the requirement that the medicine be used at the lowest effective dose and for the shortest necessary duration. Specific safety considerations are noted for older adults (due to increased cardiac risk) and for infants (due to a higher risk of neurological adverse effects).

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Моторикс (Domperidone) requires immediate action due to specific, documented risks identified in regulatory documents. Officially reported overdose manifestations primarily affect the central nervous system (CNS), including drowsiness (somnolence), disorientation, and extrapyramidal reactions (e.g., uncontrolled movements or abnormal posture).

More serious outcomes documented in regulatory labeling involve the cardiovascular system. Overdose is associated with QT interval prolongation, which is considered dose-dependent and can potentially lead to severe ventricular arrhythmias and Torsade de Pointes, with a documented risk of Sudden Cardiac Death.

Regulatory documents are explicit regarding emergency actions: individuals must seek immediate medical attention for any suspected overdose. Contact emergency services straight away if severe effects, such as convulsions or heart rhythm disturbances, are observed. Management is defined as symptomatic and supportive treatment, as no specific antidote is known. Close ECG monitoring is required due to the documented potential for cardiac events.

A population-specific consideration noted is that extrapyramidal symptoms are more likely to occur, particularly in children, following an overdose. Additionally, the elimination half-life is documented as prolonged in cases of severe renal impairment.

Therapeutic Uses of Моторикс

What Моторикс Treats: Main Uses and Benefits

Моторикс is used to help manage symptoms associated with certain gastrointestinal conditions. It is applied across domains where additional symptomatic support is needed.


Support for Symptom Clusters and Functional Strain

Моторикс is commonly used to help manage symptoms related to systemic imbalance and those that create noticeable interference with daily stability. The medicine is relevant in clinical settings marked by heightened patient distress, particularly when symptoms cluster into patterns requiring supportive management as part of acute or recurrent episodes. It is often used during phases when symptoms become more noticeable, offering supportive relief for symptoms related to physical discomfort and heightened physiological activity. This provides support that helps ease the overall symptom load and assists with maintaining functional stability.

The medicine is commonly used across conditions presenting with acute episodes and situations involving recurrent or episodic manifestations. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.

Quick Fact: May assist with support for localized symptoms.

Eligibility and Restrictions for Use

Eligibility for Моторикс (Domperidone)

The use of Моторикс is strictly defined by official regulatory criteria, detailing populations for whom the medicine is permitted, restricted, or absolutely contraindicated.

Contraindicated Populations

Моторикс is absolutely contraindicated and must not be used in the following patient groups:

  • Patients with moderate or severe hepatic impairment.
  • Individuals with known prolongation of the QTc interval or significant underlying cardiac conditions, such as congestive heart failure.
  • Patients with significant electrolyte disturbances (e.g., hypokalaemia or hypomagnesaemia).
  • Those with a prolactin-releasing pituitary tumour (prolactinoma).
  • Patients experiencing gastrointestinal haemorrhage, mechanical obstruction, or perforation.

Restricted and Conditional Use

Age Eligibility: Use is primarily established for adults and adolescents 12 years of age and weighing 35 kg. Use in children < 12 years is generally not recommended. Older adults require caution due to increased cardiac risk.

Organ Function: Patients with severe renal impairment must have a reduced dosing frequency.

Physiological States: Use during pregnancy and lactation is generally not recommended or contraindicated by regulatory bodies, as the medicine is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Моторикс (domperidone) must not be co-administered with specific medicinal products due to the documented potential for serious adverse cardiac effects, particularly QT-interval prolongation and ventricular arrhythmia. This restrictive profile is based on official government regulatory information.

Contraindicated Combinations

The most significant interaction constraint prohibits the simultaneous use of Моторикс with two categories of medicines, regardless of the patient's individual cardiac risk profile:

  • Potent CYP3A4 Inhibitors: Medicines that strongly inhibit the CYP3A4 enzyme (e.g., specific systemic azole antifungals and certain protease inhibitors). Co-administration significantly increases the plasma concentration of Моторикс, thereby escalating the risk of cardiac toxicity.
  • QT-prolonging Medicines: Any drug that is itself documented to prolong the QT interval (e.g., certain anti-arrhythmics, antibiotics, and antidepressants). This results in an additive pharmacodynamic effect, substantially increasing the risk of arrhythmia.

Precautionary Considerations

Official regulatory documents advise caution when using Моторикс with moderate CYP3A4 inhibitors (such as diltiazem) as they may still moderately increase drug exposure. Additionally, caution is advised with medicines that cause bradycardia (slow heart rate) or hypokalaemia (low potassium), as these conditions increase the pro-arrhythmic risk associated with Моторикс.

Mechanism of Action

Моторикс functions as a multimodal agent within the central nervous system, exhibiting two primary mechanistic actions to modulate neurotransmitter signaling. Its core biological target is the Sodium-dependent Serotonin Transporter (SERT), which it inhibits. This action blocks the reuptake of serotonin (5-HT) into the presynaptic neuron, resulting in an increased concentration of 5-HT within the synaptic cleft.

Simultaneously, the molecule interacts directly with multiple postsynaptic serotonin receptors. It acts as an agonist at the 5-HT1A receptor and a partial agonist at the 5-HT1B receptor. Concurrently, it serves as an antagonist at the 5-HT3, 5-HT1D, and 5-HT7 receptors. This complex receptor modulation and transporter inhibition collectively lead to an enhanced release of several key neurotransmitters, including serotonin, norepinephrine, acetylcholine, and glutamate, across specific cortical and limbic circuits. The resulting physiological consequence is the systemic alteration of monoaminergic and amino acid neurotransmission.

Dosage and Administration Information

Instruction Map: How to use Моторикс — Official Administration Guidelines

Administration Scope

Entity Instruction Details
Route of Administration Primarily Oral (tablets, suspension); Rectal (suppositories) may be an available route in specific jurisdictions.
Dosing Schedule (Adults 35 kg) Standard single oral dose is 10 mg up to three times per day. The maximum total daily dose is 30 mg.
Timing in relation to Meals Oral forms must be taken 15 to 30 minutes before meals to optimize absorption, as taking it after food delays the medicine's effect.
Preparation Requirements Liquid Oral Suspension (1 mg/mL) must be administered using a calibrated measuring device to ensure accurate dosing.
Age-Group Administration Rules Usage is restricted to adolescents 12 years of age or older and weighing 35 kg or more. For patients with severe renal impairment, the dosing frequency should be reduced to once or twice daily.
Missed-Dose Rules If a dose is missed, it should be omitted, and the regular dosing schedule resumed; the subsequent dose must not be doubled.
Special Procedural Conditions The maximum treatment duration should not usually exceed one week (7 days). Antacids or antisecretory agents must not be taken simultaneously with oral forms.

Instruction Classifications (High-Level)

Classification Principle
Administration Method Type Oral and Rectal (Jurisdiction-dependent).
Frequency Pattern Fixed interval, multiple times daily (up to three times daily).
Standardization Basis Aligned with standard pharmaceutical product characteristics.
Use-Context Constraints Time-dependent (pre-meal timing), Concomitant agent-restricted (antacids), Duration-limited (leq 7 days).

Resulting Procedural Structure

Official step sequence:

  • Administration is generally by the oral route. The 10 mg unit dose must be taken before meals. The daily dose must not exceed 30 mg.
  • The medicine is strictly restricted to adolescents 12 years or older (35 kg) and adults.
  • The total period of use should not be extended beyond the 7-day limit.

Connection to the overall use protocol (2–4 sentences): The official administration protocol establishes a maximum 30 mg daily dose and mandates pre-meal timing to ensure standardization of use. These instructions define the allowable routes, frequency, and maximum duration of treatment, while also restricting use based on patient age and the presence of severe renal impairment. This structure is based on the established procedural requirements for the medication.

Recent Clinical Evidence

Research Evidence / Overview of studies for Моторикс

Evidence for Acute Nausea and Vomiting

Research exploring the use of Моторикс for acute episodes of nausea and vomiting involves highly structured randomized controlled trials (RCTs) and comprehensive meta-analyses. These study designs were used in research exploring how symptoms change over time, applied in studies examining patient-reported experiences related to physical discomfort. The studies monitored outcomes related to episodic or acute changes in adults and adolescents.

Findings describe patterns observed in the studies, which focused on how the outcomes related to episodic or acute changes were measured. Studies reporting on acute nausea and vomiting in the populations observed contribute to the evidence for this general indication. What remains uncertain is the research base for very young patients. Data for certain groups remain insufficient, as research exploring the subpopulation of children under 12 years of age for acute vomiting is limited.

Evidence for Chronic Conditions related to Slow Stomach Movement

The research base for chronic conditions, such as gastroparesis and certain forms of functional dyspepsia, involves a mix of study types, including some randomized controlled trials and less controlled observational cohort studies. Research examined patients with conditions characterized by fluctuating symptoms.

Objective measurements of the rate of gastric emptying were key outcomes examined, alongside patient-reported outcomes describing perceived discomfort (e.g., fullness and bloating). Evidence remains limited and heterogeneous regarding the long-term outcomes studied for these chronic conditions. Long-term effects are not fully established, and regulatory reviews noted that the available data for certain chronic indications, such as functional dyspepsia, were limited, meaning certainty remains low for sustained outcomes.

Evidence in Specific Patient Groups

This medicine was studied across various age groups. Research has explored its application in specific sub-groups of adult patients, such as those with diabetic gastroparesis and groups where symptoms were refractory (unresponsive) to previous treatments.

Evidence also exists from specialized pediatric trials (RCTs) where the medicine was studied in children (e.g., aged 5 to 12 years) for conditions like functional abdominal pain. These subgroup findings are uncertain because the results apply only to the populations studied and the sample sizes were modest. Follow-up durations were limited in the most rigorous controlled trials, emphasizing that long-term effects are not fully established by the core evidence.

Frequently Asked Questions (FAQ)

Common questions about Моторикс (FAQ)

Q: Is Моторикс used for nausea and vomiting from different causes?

A: Official therapeutic indications state that Моторикс is authorized for the relief of general symptoms associated with nausea and vomiting. Regulatory documents do not specify a comprehensive list of all potential underlying causes, but focus on addressing the symptoms themselves.


Q: Is Моторикс considered an antibiotic or a different type of medicine?

A: According to official documentation, the active ingredient in Моторикс is classified as a dopamine antagonist and a prokinetic agent. This means it is classified as a medicine intended to help normalize the movement of the digestive tract, and it is not considered an antibiotic.


Q: Does Моторикс contain any ingredients that commonly cause allergic reactions?

A: The official product information lists all inactive ingredients (excipients) used in the formulation. These ingredients may include common substances such as lactose or certain parahydroxybenzoates. Regulatory documents specifically warn that some excipients, such as parahydroxybenzoates, may cause allergic reactions in sensitive individuals.


Q: How quickly does Моторикс start to relieve symptoms?

A: Published pharmacokinetic data indicate that the medicine's onset of action for its antiemetic (anti-nausea) effect is typically observed within 30 to 60 minutes after taking the oral dose. This time frame relates to how quickly the active substance is absorbed by the body.


Q: How long does the effect of a dose of Моторикс typically last?

A: The elimination half-life of the active substance in the body is approximately 7 to 9 hours in healthy individuals. This figure represents the time it takes for half of the medicine to be removed from the bloodstream, which contributes to the duration of its effect.


Q: Is Моторикс meant to be taken for a long period, or only short-term?

A: Official regulatory documents emphasize that Моторикс should be used at the lowest effective dose and only for the shortest necessary duration. The total period of treatment should not usually exceed one week (7 days).


Q: Does Моторикс interact with common over-the-counter pain relievers or cold medicines?

A: Official documents focus on warning against specific drug categories, particularly those that strongly affect the CYP3A4 enzyme or your heart rhythm. Official warnings suggest awareness of concurrent use with any medicine that falls into these restricted categories.


Q: Is it safe to consume alcohol while taking Моторикс?

A: Official public health guidance often suggests avoiding alcohol while using this medicine. Alcohol consumption may potentially worsen some side effects, such as feelings of sleepiness or risk of irregular heartbeat.


Q: Is there information about using Моторикс in children?

A: Current official use is restricted to adults and adolescents who are 12 years of age or older and weigh 35 kg or more. Regulatory reviews have concluded that the medicine is no longer authorized for use in children younger than 12 years.


Q: Does taking Моторикс affect the levels of any hormones in the body?

A: Official regulatory documents note that the medicine has been shown to produce an increase in plasma prolactin levels. Prolactin is a hormone, and an increase may be associated with certain endocrine disturbances.


Q: Is it possible for Моторикс to cause changes in menstrual periods or breast tenderness?

A: The official product information lists side effects that may affect the reproductive system. These include uncommon occurrences such as breast pain and galactorrhea (unexpected milk flow), and menstrual irregularities have also been documented in some reports.


Q: What is the typical time frame to see an improvement in symptoms with Моторикс?

A: The onset of action for anti-nausea effects is typically within 30 to 60 minutes after administration. Clinical studies related to symptom relief often focus on short-term outcomes observed within the recommended treatment duration.


Q: Do I need any special medical tests while taking Моторикс?

A: Official warnings strongly advise against using the medicine in patients with pre-existing heart conditions or significant electrolyte disturbances (imbalances in body salts). Although not required for every patient, some physicians may check these factors, such as heart rhythm (ECG) or potassium levels, to monitor cardiac risk.


Q: Can Моторикс cause problems with vision or blurry sight?

A: Vision problems are not typically listed among the common or uncommon side effects. However, official regulatory documents have mentioned that visual effects such as blurred vision may potentially occur in cases where an overdose is suspected.


Q: Why is Моторикс sometimes mentioned in discussions about milk supply?

A: The medicine is a known side effect to increase prolactin levels, the hormone associated with milk production. Although it is not licensed for this use, official documents state the medicine is excreted in breast milk and its use during lactation is generally not recommended by regulatory bodies.


Q: Can Моторикс be crushed or split if I have trouble swallowing pills?

A: Official patient instructions describe that film-coated tablets are generally intended to be swallowed whole with water and not crushed or chewed. If swallowing is difficult, an oral liquid suspension form of the medicine may be available as an alternative.


Q: Is there an official list of all the inactive ingredients in Моторикс?

A: Yes, the official regulatory documents, such as the Summary of Product Characteristics (SmPC) for each formulation, contain a full and comprehensive list of all excipients (inactive ingredients) used in the medicine.


Q: Why is Моторикс available in some countries but not in others (like the US)?

A: The US Food and Drug Administration (FDA) has not approved the medicine for general consumer use in the United States. This decision is based on safety concerns regarding the potential for serious cardiac risks, though the medicine is authorized and marketed in many other countries under their respective regulatory assessments.


Q: Is Моторикс approved for treating long-term stomach problems?

A: The medicine is generally not authorized for long-term conditions. Regulatory reviews found the evidence was limited for sustained effectiveness in chronic problems, and the authorized duration of use is restricted to not usually exceed one week (leq 7 days).


Q: Can I experience withdrawal-like symptoms if I stop taking Моторикс suddenly?

A: Health regulatory bodies have reviewed reports of psychiatric events, such as anxiety, depression, and insomnia, following the sudden discontinuation of the medicine. These reports were mostly associated with individuals taking doses higher than recommended or using the medicine outside of its authorized purpose.


Q: How does the action of Моторикс compare to other common anti-nausea medicines?

A: The medicine is officially classified as a dopamine antagonist and prokinetic agent. Official regulatory documents do not provide direct comparative claims but describe its action as primarily peripheral, meaning it affects the movement of the digestive tract.


Q: Does Моторикс work by affecting the brain or mostly the stomach/gut?

A: Official product information describes that the medicine acts primarily as a peripheral dopamine antagonist. This means its main intended effect is concentrated on the digestive tract to support the movement, with minimal penetration of the blood-brain barrier.


Q: Does Моторикс have a generic version available?

A: The active ingredient in Моторикс is Domperidone. Regulatory sources confirm that various generic domperidone products are available in countries where the drug has been authorized for sale.


Q: Does Моторикс affect the way other medicines are absorbed by the body?

A: Yes, the medicine's own absorption can be affected. Official instructions describe that certain medicines, such as antacids or those that reduce stomach acid, should not be taken at the same time as Моторикс as they may reduce the drug’s effectiveness.


Q: Is Моторикс similar to Metoclopramide (Reglan) in how it works?

A: Both medicines belong to the dopamine antagonist and prokinetic agent class, but official documents describe that Моторикс is thought to have minimal crossing of the blood-brain barrier. This is a key difference that may lead to variations in the documented side effect profile when compared to other drugs in the same class.

How should Моторикс be stored and disposed of?

Storage Conditions

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature (15 C to 30 C).
Protection Keep from freezing. Protect from excessive heat, moisture, and direct light.
Container Store in the original container and keep it tightly closed.
Child Safety Keep out of the sight and reach of children and store locked up.

Disposal Instructions

Official regulatory guidance requires that unused or expired medicine must not be thrown away via household waste or wastewater. The product must not be used after the expiry date stated on the package. Patients should consult a pharmacist for instructions on how to safely and properly dispose of the medicine in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Моторикс found in:

A-Z Index: